Coloplast ASCLPBF 73 Days Payable is 49.40 as of Mar. 2026, which is 7% below its 10-year median of 53.35. GuruFocus rates CLPBF with a GF Score™ of 73/100 and a GF Value™ of $126.92 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Coloplast AS ranks worse than 66.04% on this metric.
The historical rank and industry rank for Coloplast AS's Days Payable or its related term are showing as below:
CLPBF'
s Days Payable Range Over the Past 10 Years
Min: 48.35 Med: 53.35 Max: 58.97
Current: 50.14
During the past 13 years, Coloplast AS's highest Days Payable was 58.97. The lowest was 48.35. And the median was 53.35.
CLPBF's Days Payable is ranked worse than 66.04% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs CLPBF: 50.14
Coloplast AS's Days Payable
increased
from Mar. 2025 (47.77) to Mar. 2026 (49.40).
It may suggest that Coloplast ASdelayed paying its suppliers.
Coloplast AS Days Payable Related Terms
Coloplast AS Days Payable Historical Data
* Premium members only.
The historical data trend for Coloplast AS's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Coloplast AS's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coloplast AS Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Coloplast AS's Days Payable distribution charts can be found below:
* The bar in red indicates where Coloplast AS's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Coloplast AS's Days Payable for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coloplast AS (CLPBF) has a Days Payable of 49.40 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Coloplast AS and its competitors. This is near median its historical median of 53.35. Over the past decade, Coloplast AS's Days Payable has ranged from 48.35 to 58.97. According to the industry distribution chart, Coloplast AS ranks #525 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 66%.
Is Coloplast AS's Days Payable too high?
Coloplast AS's current Days Payable of 49.40 is near median its 10-year median of 53.35. Over the past 10 years, this metric has ranged from a low of 48.35 to a high of 58.97. The Medical Devices & Instruments industry median Days Payable is 67.87. Coloplast AS's value of 49.40 is 27.2% below this industry median. Based on the distribution chart, Coloplast AS ranks #525 out of 795 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Coloplast AS has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's Days Payable compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Coloplast AS ranks #525 out of 795 companies for Days Payable. This places Coloplast AS in the lower half of its industry. The industry median Days Payable is 67.87. Coloplast AS's value of 49.40 is 27.2% below this benchmark. Historically, Coloplast AS's own Days Payable has ranged from 48.35 to 58.97 over the past decade. While the company's 10-year median is 53.35 vs. the industry median of 67.87, Coloplast AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coloplast AS's current Days Payable of 49.40 is 27.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Coloplast AS and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coloplast AS's current Days Payable is 49.40, which is near median its own 10-year median of 53.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (CLPBF) is currently considered Significantly Undervalued. The stock's GF Value™ is $126.92, compared to a current price of $57.41 — trading 54.8% below its estimated fair value. The current Days Payable is 49.40, which is near median its 10-year median of 53.35 and 27.2% below the Medical Devices & Instruments industry median of 67.87. Coloplast AS's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Coloplast AS (CLPBF), the current Days Payable is 49.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coloplast AS (CLPBF) Overvalued in 2026?
Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued.
The current stock price of $57.41 is trading 54.8% below its estimated GF Value™ of $126.92.
GuruFocus considers Coloplast AS to be Significantly Undervalued.
Key valuation signals for CLPBF:
Days Payable: 49.40 (near median its 10-year median of 53.35)
GF Value™: $126.92 vs. price of $57.41 (54.8% below fair value)
Industry Position: 27.2% below the Medical Devices & Instruments median (#525 of 795)
No single metric tells the full story. See the CLPBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
73GF Score
Get the complete analysis for CLPBF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPBF has been successfully added to your 
